A single-arm, phase II clinical study of imatinib mesylate/toripalimab combo in patients (pts) with advanced melanoma harboring c-Kit mutation or amplification

L. Si, Z. Qi, J. Dai, X. Bai, L. Mao,C. Li, X. Wei,C-L. Cui, Z. Chi, X. Sheng, Y. Kong, T. Bixia, L. Zhou,B. Lian,X. Wang, R. Duan,J. Guo

ANNALS OF ONCOLOGY（2022）

引用 0|浏览0

暂无评分

摘要

Kit inhibitor monotherapy has moderated activity in melanoma harboring c-Kit aberrations (CKA) but with an unsatisfied objective response rate (ORR) of 23-26% and median progression free survival (mPFS) of 3.5-7.3mo. Thus we performed a phase II trial testing the imatinib mesylate/toripalimab (anti-PD-1 monoantibody) combo in pts with advanced melanoma harboring CKA. (NCT: 05274438).

查看译文

关键词

advanced melanoma,imatinib mesylate/toripalimab,mutation,single-arm,c-kit

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要